November 5th, 2018

GlyCoCan – watch the video on biomarker potential of glycosylation in colorectal cancer prepared by GlyCoCan Early Stage Researchers

Colorectal cancer is a life-threatening disease affecting the large bowel. Improved diagnostic methods could notably increase the chance of a disease-free life due to a timely diagnosis followed by effective, personalized treatment. Genos is a partner in GlyCoCan, a network focused on colorectal cancer research in the field of glycobiology, which connects 13 PhD students and their experienced mentors all across Europe. By investigating the role of glycans (complex carbohydrates present on human cells including cancer) they are paving the way for precision medicine in the field of oncology.

July 15th, 2017

EFRD project: Genos has signed Euro 3.057 million valued project “New Generation of High-Throughput Glycoanalytical Services

Genos is proud to announce that it has signed a new three-year R&D contract with the Croatian Ministry of Economy, Enterpreneurship and Crafts  and HAMAG-BICRO agency. Under this contract Genos will coordinate the R&D project “New Generation of High-Throughput Glycoanalytical Services” aimed at the development of novel high-throughput analytical methods in glycobiology. Additional project partners are University of Zagreb Faculty of Pharmacy and Biochemistry, University of Zagreb Faculty of Science and University of Rijeka, Department of Biotechnology. Total value of the project is Euro 3.057 million. The majority of the costs (79%) will be provided by the European Fund for Regional Development,  European Structural and Investment Funds (ESI Funds), Call “Increasing the development of new products and services arising from research and development activities”.while the remaining 21% will be funded by project partners.

Glycobiology was featured as a new and rapidly advancing field of science in July 6th issue of Nature. In 2012, the US National Research Council warned that ignoring glycans would impair research in biomedicine. Since 2015, the Common Fund of the NIH has awarded 49 grants totalling US$29.2 million as part of its glycoscience programme. Genos is already dominating the global market of high-throughput glycomics for clinical and epidemiological studies. New analytical methods, which will be developed through this project, will enable Genos to expand its participation in large research projects and perform analytical service to researchers from all around the world.

July 12th, 2017

PhD position in bioinformatics available as a part of H2020 project “ Innovative training in methods for future data (IMforFUTURE)”

As part of the IMforFUTURE initiative (, 11 scientist positions are being established, which we wish to fill with exceptional researchers (m/f) from the fields of statistics, bioinformatics, genetics and glycoproteomics. The positions are located in different laboratories across Europe and provide a stimulating collaborative approach within a cutting-edge research environment.

IMforFUTURE is a Marie Sklodowska-Curie Innovative Training Network (MSCA-ITN-ETN). We offer an innovative multidisciplinary and intersectoral research training programme in statistics, integrated data analysis, glycoproteomics and genetics and glycoproteomics analysis.The aim is to integrate genetics, glycomics, and epigenomics datasets into systems biology for ageing by developing innovative methods for high throughput omics and for integrative analysis of omics data. The network brings together renowned experimental and theoretical scientists from six universitiesand two industrial companies across Europe.

Genos Ltd. is a research intensive SME located in Zagreb, Croatia. Genos is currently the global leader in high-throughput glycomics for clinical and epidemiological studies. We have analysed over 20,000 samples in the last two years and have established collaborations with numerous leading research institutions in Europe, USA, China and Australia. As a partner, Genos has participated in 6 FP7 and 4 H2020 projects. Our main competitive edge is the know-how and experience in performing high throughput studies, ranging from analytical chemistry to study design and statistical data analysis. In its 2013 survey, The Scientist magazine ranked Genos as the “Best place to work” for researchers in industry in the world.

We are seeking a highly-motivated PhD student in data analysis who will join Genos Glycoscience Group to work on data mining and omics integration in complex biological problems of genetics of protein glycosylation. A successful candidate will work within vibrant environment of interdisciplinary team of data analysts, molecular biologists and chemists to overcome technical and experimental obstacles in high-throughput glycomics. With increasing evidence of importance of glycosylation in various physiological conditions, integrating glycomics with other omic layers (such as SNP variome, methylome, transcriptome and gut microbiome) represents major focus of our work and provides a step forward in understanding complex mechanisms underlying human diseases.

As an Early Stage Researcher in Genos Ltd., you will undertake research in integrative analysis of glycomics data, with emphasis on the genetics of protein glycosylation encompassing all stages of data analysis, starting from the study design and statistical data cleaning to complex analyses of multiple omics datasets. You will interact and develop research collaborations with our IMforFUTURE academic partners, and in addition you’ll participate in activities of the Innovative Training Network, including attending training courses and visiting other sites.

To meet the requirements of the Marie Skłodowska-Curie Innovative Training Network, you will be an early stage researcher within the first four years of your research career, have not yet been awarded a doctoral degree (PhD), and have not lived or carried out your main activity (work/study) in the Croatia for more than 12 months during the past 3 years. You will also need to have the flexibility to travel throughout the European Union.

As well as previous research experience, you will have a good Masters’ degree in bioinformatics, computational biology or similar, alternatively in computer sciences with experience in molecular biology large-scale data analysis and be eligible to enrol on a PhD degree. You’ll also have excellent communication and organisational skills and a strong commitment to your own professional development.

What does the role entail?

As an Early Stage Researcher your main duties will include:

  • Contributing to the IMforFUTURE Innovative Training Network (ITN) ;
  • Undertaking ongoing research at doctoral degree level into integrative analysis of glycomics data;
  • Participating in IMforFUTUREITN activities to ensure a successful programme of investigation, including attending group meetings and seminars, training courses and site visits; as well as collaborating with academic and industrial partners;
  • Contributing to the dissemination of research results in leading peer-reviewed journals and through presentation at meetings and conferences, with guidance as necessary;
  • Ensuring good progress of your work and keeping up-to-date records;
  • Providing support and advice to other members of the ITN;
  • Working both independently and as part of a larger team of researchers and stakeholders;
  • Continually updating your knowledge, understanding and skills in the research field in which you work.

These duties provide a framework for the role and should not be regarded as a definitive list. Other reasonable duties may be required consistent with the grade of the post.

What will you bring to the role?

As an Early Stage Researcher you will have:

  • A good Masters’ degree in bioinformatics, computational biology or similar, alternatively in computer sciences with experience in molecular biology large-scale data analysis;
  • Basic understanding of statistical concepts and machine learning methods
  • Experienced in the use of a programming language R
  • The ability to meet all eligibility requirements for appointment in the Croatia as an Early Stage Researcher funded by the Marie Skłodowska-Curie Innovative Training Network:

–                 You must be within the first four years (full-time equivalent) of your research career, and have not yet been awarded a doctoral degree (e.g. PhD), at the time of recruitment to this role;

–                 You must not have resided or carried out your main activity (such as work or study) in the Croatia for more than 12 months during the 3 years prior to your recruitment to this role;

  • Interdisciplinary communication and English language skills
  • The flexibility to travel throughout the European Union;
  • Experience of undertaking academic research;
  • Good interpersonal and communication skills, both written and verbal, and the ability to communicate effectively with a wide range of stakeholders;
  • Good time management and planning skills, with the ability to meet tight deadlines and manage competing demands effectively;
  • A proven ability to work well both independently and as part of a team;
  • A strong commitment to your own continuous professional development.
  • Knowledge of Biology and Medicine.

How to apply?

Apply by submitting the following:

  • CV (imforfuture_LastName_FirstName_CV),
  • motivational letter (imforfuture_LastName_FirstName_ML), and
  • 2 recommendation letters (imforfuture_LastName_FirstName_RL)

to the email address:

November 10th, 2016

PhD positions available as part of a Marie Curie Innovative Training Network

Six PhD positions are offered as part of a Marie Curie Innovative Training Network composed of 3 leading European partners in the fields of glycobiology, glyco-immunology and biomarker research. Research and the training will be carried out at the Center for Proteomics and Metabolomics (CPM) at the LUMC in Leiden, Ludger in UK, Genos (Croatia) and Max Planck Institute (Germany).Continue reading

October 29th, 2015

GLYCO23 – Lectures from the pre-conference training course ”Introduction to Glycoscience”

For the first time Glyco 23 introduced a pre-symposium training course “Introduction to Glycoscience” with introductory lectures by leading experts in the field. We hope that these lectures helped our young colleagues, but also experienced researchers from other disciplines, to better understand the dynamic and rapidly evolving field of glycoscience.
We are happy to announce that those lectures are now available online on the Genos-glycoscience website.

Lecture 1: Introduction to Glycan Structure

Anne Dell (Imperial College London, UK)

Lecture 2: Ubiquitous Importance of Protein Glycosylation

Gordan Lauc (Faculty of Pharmacy and Biochemistry, University of Zagreb; Genos Glycoscience Research Laboratory, Croatia)

Lecture 3: Sialic acids in the fine tuning of neurological processes

Rita Gerardy-Schahn (Hannover Medical School, Germany)

Lecture 4: Glycan Chip Technology

Sabine Flitsch (University of Manchester, UK)

Lecture 5: Mysterious World of O-GlcNAc

John A. Hanover (NIDDK, National Institutes of Health, USA)

August 28th, 2015


INTERNATIONAL SYMPOSIUM ON GLYCOCONJUGATES Genos is one of the sponsors of Glyco23, 23rd International symposium on glycoconjugates. The meeting will be held in Split, Croatia, September 15th to 20th, 2015.

International Glycoconjugate Organization Logo

Experts in glycobiology will give lectures in around twenty sessions, with addition of Young Glycoscientists’ Symposium and guest sessions of the Society for Glycobiology (SFG) and Asian Community for Glycoscience and Glycobiotechnology (ACGG). For the first time this year, pre-symposium training course “Introduction to Glycoscience” will be held by leading experts in the field.

May 18th, 2015

Prof. Gordan Lauc PhD, was awarded with the Croatian State Award for 2013 in the field of biomedical sciences

Prof. Gordan Lauc PhD is CEO of Genos and Professor of Biochemistry and Molecular Biology at the University of Zagreb Faculty of Pharmacy and Biochemistry. His research interest is focused on two fields: glycoproteomics and forensic genetics and molecular diagnostics. He has been recognized globally, and this is confirmed by his involvement in a number of international research consortia and numerous invitations to hold lectures. He is among few Croatian scientists to have his research project approved by the National Institutes of Health (NIH), USA. He has coordinated or been one of the main researchers on twelve FP6 and FP7 projects. He has published more than 100 scientific papers in journals cited in the Current Contents database, as well as other forty scientific papers and chapters in books. His scientific papers have been cited approximately 1000 times.

May 16th, 2015

The Croatian State Awards for Science presented – Prof. Gordan Lauc PhD, awarded in the field of biomedical sciences

This year, Prof. Gordan Lauc PhD, was awarded in the field of biomedical sciences for important achievement in his research of glycoms, i.e. N-glycosylation of proteins. At the ceremony in the Croatian Parliament, held on 27th October 2014, the Croatian State Awards for Science were presented to scientists and researchers for their important achievements in different scientific fields. This includes achievements in natural sciences, technical sciences, biomedical sciences, biotechnological sciences, social sciences and humanistic sciences.

May 15th, 2015

Interview with Prof. Gordan Lauc PhD in Glas Slavonije (The Voice of Slavonia)

Formal recognitions, like the Charter of the Republic of Croatia or the Croatian State Award for Science are confirmation that a job is done well. Such recognitions are especially important for small firms, like Genos Ltd., who spare no effort to make a change. Unfortunately, it is customary in our community to believe that if something is imported from abroad, it should be better than what we do here in Croatia. I hope the fact that the highest state institutions (the Croatian Parliament and the President of the Republic of Croatia) have recognized our quality and presented us with important recognitions will help this promising young firm to develop further,” points out Prof. Gordan Lauc.

You can see the original interview here.

May 8th, 2015

Outstanding recognition – the President of the Republic of Croatia, Ivo Josipović, conferred the Charter of the Republic of Croatia on Genos

On the occasion of Statehood Day, the President of the Republic of Croatia, Ivo Josipović, conferred decorations on distinguished individuals, companies, and associations for their services and contributions. In the presence of highest state bodies, accredited ambassadors to Croatia, representatives of business, scientific, cultural, and sports organizations, as well as leaders of religious communities, the decorations were conferred on a ceremony in the Croatian National Theatre in Zagreb, on Wednesday 25th June 2014.

May 7th, 2015

Genos – Best Place to Work

Genos Ltd, a research-intensive SME located in Zagreb that performs contract research, contract analysis and service for numerous universities, hospitals and private individuals in Europe and overseas specialising in molecular genetics and glycomics, has been recognised by the respected magazine.

The Scientist based their list on a survey which included responses from 240 companies. Survey participants were asked to assess their work environment according to 43 criteria in eight different categories including research environment, integrity, management, communications, job satisfaction, and training and development. Other international companies in the top ten included Acceleron, Vitae Pharmaceuticals, OpenEye Scientific Software, Inc., Wyatt Technology Corporation, Genentech, Millennium: The Takeda Oncology Company, Integrated DNA Technologies, Regeneron Pharmaceuticals, and Monsanto.

May 6th, 2015

Genos – The Most Innovative SME in Croatia

Results of the second national research on innovativeness of Croatian companies were presented at VERN University of Applied Sciences. A consulting company Sense Consulting, weekly magazine Lider, and VERN used the sample of 300 Croatian companies of different profiles in their research. Genos has been named as the most innovative SME in Croatia.

May 5th, 2015

Large International Consortium Led by Croatian Scientists Has Made a Significant Discovery

Scientists from the company Genos were the leading scientists in a large international consortium that came to a significant discovery related to autoimmune diseases and tumours. The discovery of the consortium opens up a new area for development of medicines and diagnostics of autoimmune diseases and tumours.

One of the most respectable magazines in the field of genetics, PloS Genetics, published an article titled “Loci Associated with N-Glycosylation of Human Immunoglobulin G Show Pleiotropy with Autoimmune Diseases and Haematological Cancers” at the beginning of this year, revealing a net made of 16 genes that control glycosylation of immunoglobulin. The revealed genes are important in understanding a large number of autoimmune diseases and tumours, and this indicates the significance of glycosylation of immunoglobulin in development of the mentioned diseases, as well as it opens up a new area for development of diagnostics and new medicines.

The research was carried out as part of a large international consortium that included scientific institutions from Scotland, Ireland, the Netherlands, England, USA, China, Australia, Sweden, and Russia. Nevertheless, the entire analysis of glycosylation of immunoglobulin, the basis for this research, was carried out in Genos laboratory in Zagreb, which once again confirmed the leading role of Genos’ scientists in the field of glycomics globally.